Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer

Inclusion Criteria: * 1\. Voluntarily enroll in the study, sign the informed consent form, and be willing and able to comply with the study protocol. * 2\. Aged ≥18 years and ≤70 years. * 3\. Recurrent or metastatic cervical cancer: have received prior adequate first-line systemic therapy with radiologically confirmed disease progression during or after treatment. * 4\. Have at least one resectable tumor lesion for the manufacture of autologous tumor-infiltrating lymphocytes (TILs). * 5\. Apart from the sampling lesion(s), have at least one measurable lesion per RECIST 1.1. * 6\. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * 7\. Expected survival ≥12 weeks. * 8\. Adequate normal organ and bone marrow function. * 9\. Serum human chorionic gonadotropin (HCG) test must be negative within 7 days prior to TIL infusion for women of childbearing potential without surgical sterilization. * 10\. Adverse events from prior therapies must have recovered to Grade ≤1 (per CTCAE 5.0) before tumor sampling. * 11\. Participants entering this study due to disease progression must have radiological documentation of disease progression following the last prior treatment before tumor resection. Exclusion Criteria: * 1\. Spinal cord compression not relieved by surgery and/or radiotherapy is exclusionary. * 2\. Uncontrolled tumor-related pain as judged by the investigator. * 3\. Bleeding events occurring within 3 months prior to screening. * 4\. Arterial or venous thromboembolic events within 6 months prior to screening, such as cerebrovascular accident, deep vein thrombosis (DVT), pulmonary embolism (PE), etc. * 5\. Respiratory diseases that substantially impair pulmonary function. * 6\. History of clinically significant cardiovascular disease. * 7\. Participants with untreated central nervous system (CNS) metastatic lesions at screening. * 8\. Active autoimmune disease requiring systemic corticosteroids or immunosuppressive therapy. * 9\. Malignancies other than the target indication diagnosed within 5 years before screening. * 10\. Refractory/intractable epilepsy, medically uncontrolled pleural effusion, etc. * 11\. Infectious diseases within 1 year prior to screening. * 12\. Use of anti-angiogenic agents within 4 weeks before sampling. * 13\. Prior allogeneic hematopoietic stem cell transplantation or solid organ transplantation. * 14\. Systemic anti-tumor therapy administered within 4 weeks prior to lymphodepleting chemotherapy. * 15\. Prior receipt of genetically modified or edited cellular therapy products. * 16\. History of allergic reaction to any component of the investigational agents to be used in this study. * 17\. Known psychiatric disorders, alcohol abuse, illicit drug use, or substance abuse. * 18\. Prior immunotherapy associated with Grade ≥3 immune-related adverse events (irAEs) that failed to recover to CTCAE Grade 1 or lower within 28 days. * 19\. Pregnant or lactating women, or women planning pregnancy, gestation or lactation within 1 year after cell infusion. * 20\. Receipt of other investigational medicinal products within 4 weeks prior to randomization, or plan to receive other investigational medicinal products during the study. * 21\. Other conditions judged unsuitable for enrollment by the investigator.